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Chemotherapy of Chagas disease remains a major 
challenge in the Americas. As a result of sustained cam-
paigns of vector control, the number of new infections in 
endemic areas has decreased, but the disease still afflicts 
10-15 million people in Latin America (Schofield et al. 
2006). No satisfactory treatment for Trypanosoma cruzi 
infection is available (Pérez-Molina et al. 2009); currently 
used drugs are toxic and have disputable efficacy in the 
treatment of chronic infections (Marin-Neto et al. 2009).
Tamoxifen is a triphenylethylene that has been in 
clinical use for the treatment and chemoprevention of 
breast cancer since 1971 (Jordan 2003). It has been shown 
to inhibit the growth of promastigotes and intracellular 
amastigotes of several species of Leishmania (Miguel et 
al. 2007, 2009). Tamoxifen was also effective against the 
parasite in vivo, as shown in various experimental ro-
dent models of visceral and cutaneous leishmaniasis. In 
all models tested, parasite burden and/or lesion progres-
sion decreased significantly after intraperitoneal admin-
istration of 20 mg/kg/day tamoxifen for 15 days (Miguel 
et al. 2008, 2009).
Leishmania and Trypanosoma belong to the Try-
panosomatidae family, are genetically related and share 
many biochemical pathways, as shown by comparative 
analysis of their respective genomes (El-Sayed et al. 
2005) and by comparative biochemical studies (Michels 
et al. 2006, Landfear 2008, Stuart et al. 2008). In this 
study, we evaluated the activity of tamoxifen against T. 
cruzi in vitro and in vivo.
The T. cruzi strains used were CL-14 (Brener & Chiari 
1963), Y (Silva & Nussenzweig 1953) and a benznidazole-
resistant line derived from the Y strain (BZR) (Murta & 
Romanha 1998). Epimastigotes were grown in liver in-
fusion-tryptose medium (LIT) supplemented with 10% 
fetal calf serum (FCS) and maintained at 25ºC (Camargo 
1964). The activity of tamoxifen (Sigma-Aldrich) against 
epimastigotes was assayed by counting the number of mo-
tile forms in a hemocytometer after incubating parasites 
with increasing concentrations of the drug for 24 h.
To analyze the effect of tamoxifen on intracellular 
parasites, metacyclic trypomastigotes harvested from LIT 
cultures at the stationary growth phase were used to infect 
LLC-MK2 (rhesus monkey kidney, ATCC-CCL7) cells at 
a ratio of 50:1 parasites/host cell. Cultures were main-
tained at 34ºC and 5% CO2 in Roswell Park Memorial 
Institute (RPMI) medium (Sigma-Aldrich), supplemented 
with 2% FCS for 24 h, washed to remove free parasites 
and then incubated for 48 h with increasing concentra-
tions of tamoxifen. Infected cells were maintained at 34ºC 
in an atmosphere of 5% CO2 and the medium
 was replaced 
every 24 h. After drug exposure, the untreated and treated 
infected cell cultures were fixed and stained with the In-
stant Prov kit (Newprov, Pinhais, Brazil). The number of 
infected host cells was determined using at least 400 host 
cells for two independent experiments run in triplicate.
Trypomastigotes were obtained from the blood of in-
fected mice. To obtain sufficient numbers of parasites 
for drug susceptibility tests, these trypomastigotes were 
used to infect Vero cell cultures, which were maintained 
at 37ºC and 5% CO2 in Dulbecco’s Modified Eagle’s 
Medium supplemented with 10% FCS, as previously de-
scribed (Santos 2008). Trypomastigotes released on the 
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The activity of the antineoplastic drug tamoxifen was evaluated against Trypanosoma cruzi. In vitro activity was 
determined against epimastigote, trypomastigote and amastigote forms of CL14, Y and Y benznidazole resistant T. 
cruzi strains. Regardless of the strain used, the drug was active against all life-cycle stages of the parasite with a half 
maximal effective concentration ranging from 0.7-17.9 µM. Two experimental models of acute Chagas disease were 
used to evaluate the in vivo efficacy of treatment with tamoxifen. No differences in parasitemia and mortality were 
observed between control mock-treated and tamoxifen-treated mice.
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culture supernatant were recovered after 6-8 days, resus-
pended in RPMI without phenol red and incubated with in-
creasing concentrations of tamoxifen for 24 h at 37ºC. The 
number of viable parasites was then assessed using the vi-
tal stain Alamar Blue (Invitrogen). Parasites were incubat-
ed with 10% Alamar Blue for 24 h at 37ºC and the reduc-
tion of resazurin was monitored at 570 nm using 600 nm 
as a reference wavelength (Santos 2008). The percentage 
of viable cells was determined by comparison with con-
trol untreated cultures.
The half maximal effective concentration (EC50) val-
ues for the T. cruzi populations were determined from 
sigmoidal regression of the concentration-response 
curves using Scientific Graphing and Analysis Software 
Origin 5.0. Experiments were performed in triplicate 
and repeated at least twice.
In vivo experiments were approved by the Ethical 
Committee for Animal Experimentation of the Institute 
of Biomedical Sciences of São Paulo University (approval 
certificates 033/07 and 067/08). Animals were bred, han-
dled and maintained according to the Brazilian rules and 
regulations of animal experimentation. Acute infections 
were performed as described (Filardi & Brener 1987). 
BALB/c and Swiss Webster female and male mice were 
used (8-10 animals/experimental group). Infections were 
initiated by intraperitoneal inoculation of 5,000 T. cruzi 
Y strain tissue culture trypomastigotes/Swiss Webster 
mouse and 500 parasites/BALB/c mouse, due to the in-
creased sensitivity of BALB/c mice to infection. Tamox-
ifen treatment was initiated on the 4th day of infection for 
Swiss Webster mice and on the 2nd day for BALB/c mice. 
Tamoxifen citrate was tested at 10, 20, 25 and 50 mg/kg/
day of drug equivalent for 15-20 days. Benznidazole (BZ) 
(Rochagan, Roche Co) was used as a reference drug at 
100 mg/kg/day. Infected animals that received only saline 
were used as control groups. Parasitemia was assessed 
every other day from the 2nd day of infection by count-
ing the trypomastigotes in a 5 µL blood sample obtained 
from the tail vein. Surviving animals were monitored for 
60 days and then subjected to hemoculture, used as a cri-
terion of cure (Brener 1962). Tamoxifen citrate (6 mg/mL) 
and BZ (6.25 mg/mL) solutions were prepared in 150 mM 
NaCl, pH 7.2-7.4.
The table shows the in vitro activity of tamoxifen 
against T. cruzi strains and life stages. The drug was ac-
tive against all T. cruzi life stages tested, with increased 
susceptibility noted for the infective mammalian stages, 
trypomastigotes and amastigotes. EC50 values calculated 
for epimastigotes of CL14, Y and BZR strains were simi-
lar, indicating homogeneous sensitivity between different 
strains and showing that resistance to BZ does not have an 
impact on sensitivity to tamoxifen.
The efficacy of tamoxifen in the control of acute in-
fections was initially tested in female Swiss mice (Figs 
1-3). Parasitemia peaks were reached at the 8th day after 
infection. The treatment of infected mice with 10, 25 or 
50 mg/kg/day of tamoxifen for 15-20 days did not alter the 
parasitemia curves as compared to control mock-treated 
groups, whereas parasitemia was undetectable in BZ-
treated mice (Figs 1-3). Previous experiments in leishma-
niasis experimental models did not identify any differenc-
es between male and female responses to treatment with 
tamoxifen (Miguel et al. 2008). However, other research 
(de Souza et al. 2001) suggests that oestradiol may inter-
fere in the outcome of T. cruzi infection in C57BL/6 fe-
male mice and, in a less pronounced way, in BALB/c and 
C3H mice. Therefore, we decided to evaluate tamoxifen 
effectiveness in infected male Swiss mice (Fig. 4). No dif-
ferences were detected in the response of male vs. female 
mice and tamoxifen treatment was completely ineffective 
in the control of parasitemia.
Acute T. cruzi infections in another mouse model were 
also performed. BALB/c mice infected with T. cruzi Y 
also developed parasitemia peaks at the 8th day post-in-
fection. Male or female BALB/c mice treated with 20 mg/
kg/day tamoxifen for 15 days showed no reduction in par-
asitemia levels when compared to control animals. In con-
trast, parasitemia reached a peak in BZ-treated BALB/c 
mice around the 7th-8th day post-infection and became 
negative by the 23rd day post-infection (Fig. 5).
Another parameter assessed was the survival rate. 
While no mortality was detected in BZ-treated groups up 
to 60 days after infection (in Swiss Webster or BALB/c 
mice), animals treated with tamoxifen did not survive lon-
ger than control untreated groups, confirming the lack of 
antitrypanosomal activity of tamoxifen in these models of 
infection (Figs 1-5). Because there were no survivors in ta-
moxifen-treated and untreated groups, only the BZ-treated 
Swiss Webster mice were subjected to hemoculture. The 
cure rate was 70%, as expected for the partially-resistant T. 
cruzi Y strain when infecting Swiss Webster mice.
The current chemotherapies of leishmaniasis and Cha-
gas disease do not include drugs that are effective against 
both diseases. However, the novel anti-leishmanial activ-
ity of tamoxifen (Miguel et al. 2007, 2008, 2009) inspired 
curiosity about a possible common target between these 
organisms and led to the investigation of an anti-Trypano-
soma effect. The results shown here indicate that tamox-
TABLE
In vitro activity of tamoxifen against 
Trypanosoma cruzi strains and life stages
Strain Life stage EC50 ± SD (µM)
a
CL14 Amastigote 2.7 ± 1.1
CL14 Epimastigote 17.9 ± 3.3
Y Epimastigote 12.3 ± 2.1
BZR Epimastigote 16.1 ± 2.6
Y Trypomastigote 0.7 ± 0.1
BZR Trypomastigote 0.7 ± 0.1
a: values are expressed as means ± standard deviation (SD) of 
at least two independent experiments performed in triplicates. 
EC50: tamoxifen effective concentration that decreases the 
number of viable parasites by 50% (in 24 h for epimastigotes 
and trypomastigotes and in 48 h for amastigotes).
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ifen is indeed active against both parasites. Data from in 
vitro tests, which demonstrated activity against the dif-
ferent T. cruzi life forms in the same order of magnitude 
as encountered for Leishmania spp, were initially very 
encouraging. However, despite the marked in vitro activ-
ity against two T. cruzi strains, tamoxifen did not prolong 
life or decrease parasitemia in experimental models of 
acute infection with T. cruzi. The therapeutic schemes 
in the present work included doses up to 2.5-fold greater 
than the effective doses for the treatment of leishmaniasis 
(Miguel et al. 2008, 2009) and data presented here were 
obtained independently in two laboratories.
While the in vitro results indicate the shared presence 
of the tamoxifen biochemical target(s) in both organisms, 
undetermined factors prevent tamoxifen activity in vivo 
against T. cruzi. Whereas Leishmania preferentially para-
sitises macrophages in the mammalian host and localizes 
preferentially in organs of the mononuclear phagocytic 
system, T. cruzi can inhabit most types of differentiated 
cells and has a wide organ distribution, especially in the 
acute form of the disease. Tamoxifen has been shown 
to accumulate in organs such as liver, bone marrow and 
adipose tissue, while only a minor portion of the drug re-
mains in the serum (Lien et al. 1991). Differential tissue 
permeability and accumulation could explain the different 
outcomes of tamoxifen treatment. We cannot exclude that 
other factors, such as interference in immune-mediated 
defence mechanisms, are also of importance.
Beyond demonstrating that tamoxifen is ineffective 
against T. cruzi infections, these results also highlight the 
importance of using in vivo studies to validate new candi-
dates for chemotherapy.
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Figs 1-5: tamoxifen treatment of Trypanosoma cruzi acute infections in mice. Swiss Webster female (1-3) or male (4) mice and BALB/c female 
and male mice (5) were infected with T. cruzi Y strain. Treatment was started on the 4th day (1-4) or on the 2nd day (5) post-infection and para-
sitemia evaluated every other day by tail vein puncture. Animals were treated with tamoxifen (squares) at 10 (1), 25 (2), 50 (3,4) or 20 mg/kg/day 
(5) for 15-20 days. Parasitemia curves from mock-treated animals (diamonds) and from animals that received 100 mg/kg/day benznidazole (BZ) 
(triangles) were also obtained. Results are expressed as the mean of two independent experiments. Standard deviation is shown as a plus sided 
bar. The arrows indicate the period of treatment with tamoxifen or BZ. †S, †T: death of all animals from saline or tamoxifen-treated groups, 
respectively (n = 8-10 animals per group).
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